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Smry Whole bladder wall photodynamic thepy (PDT) with haematoporphyrin derivative and an argon
dye laser as a light source was performed on 34 patients with refractory carcinoma in situ (CIS) of the bladder.
Twenty-five of the 34 patients (73.5%) had achieved a complete resonse.(CR) at 3 months after the
treatment. The median follow-up for these CR patients is 49.3 months. Although recurrene within 2 years of
follow-up occurred in 14 (77.8%) of the 18 CR patients followed to that point, since most of the recurrent
tumours were superficial and low-grade papllary tumours, resection of the bladder tumours
appeared to be sufficent. Of the total of 34 patents, ten were aliv with bladder intact with a mean follow-up
period of 64.0 months. Skin photoseritity and transient e in bladduer capacity were noted as adverse
reactions, caused by retention of hadmatoprphyrn deivative in the skin and normal portion of the bladder.
These data suggt that PDT can be an effective form of therapy for CIS of the bladder.
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The behaviour of carcinoma in situ (CIS) of the bladder is
variable, and it has been reported that most invasive bladder
cancers progress from CIS (Utz et al., 1970; Prout et al.,
1983). Many investigators have performed intravesical
administaion of various kinds of cytotoxic agents or bacil-
hls Calmette-Guerin (BCG). Repeated courses of intra-
vesical BCG or chemotherapeutic agents have been shown to
be effective in patients with CIS (Herr et al., 1986; Prout et
al., 1987). However, adverse reactions to such treatments are
not negligible (Lamm et al., 1986), and the risk of invasive
(30%) or metastatic (50%) cancer developing exceeds the
prospects of eradicating the superficial tumour present with
further therapy in patients in whom two or more courses of
BCG therapy have failed (Catalona et al., 1987). A more
radical approach is total cystectomy. However, such major
operations including urinary diversion may result in the
restriction of social and sexual activities. The effectiveness of
photodynamic therapy (PDT) ming haematoporphyrin
(HpD) as a photosensitiser was reported by Dougherty et al.
(1979) for the conservative treatment of certain cancers, and
increasing attention has been focused on this new treatment
technique. On exposure to light of an appropriate
wavekngth, photosensitising compounds udergo a
photochemical reaction resultng in the in situ production of
reactive oxygen radicals that are lethal to the cell. The com-
pound HpD has an affinity for malignant tissue, and thus
seective desuction of the tumour is possibe. Over the past
decade, 34 patients with superficial bladder cancers, partic-
ularly with CIS, have been treated with PDT at our insti-
tution. Here, the authors evaluate not only the immediate
therapeutic clinical efficacy of PDT 3 months after the treat-
ment, but also the long-term outcome of this treatment.
Padeus and methos
We studied 34 patients who had received frequent transure-
thral (TUR) of the bladder cancer, local hyperthermia and/or
intravesical insillation of chemotherapeutic agents before
PDT. In all patients total cystectomy and urinary diversion
had ether been refused, or this treatment had been contrain-
dicated. The patients were 30 - 81 years old (mean age
63.4±11.6). Thirty were men and four were women. CIS
and/or tumours were confirmed by bladder biopsy and
urinary cytological examination. The patients were sub-
divided into three categories, consisting of four with primary
CIS, 12 with secondary CIS and 18 with superficial tumours
associated with CIS. PDT was performed at least 4 weeks
after transurethral tumour resection or biopsies of the blad-
der. Twenty-one patients were injeled with 3 mg kg-' body
weight Photofrn I (Oncology Research & Development,
Chicktowaga, NY, USA), which was produced according to
Lipson's method, and 13 patients received 2mglkg-' body
weight Photofrin U, which is a dihaematoporphyrin ester/
ether purified further than Photofrin I, in most cases 72 h
before the PDT. The patients were advised to avoid exposure
to sunlight for up to 4 weeks. Red laser light (630±5 nm)
was provided by an argon pumped ion laser (Spectra-Physics
modes 375-03 and 171-07). PDT was performed based on
our data obtained with preliminary experiments using a
spherical glass flaskl as a model of the bladder. Either a
motor-driven scattering or endoscope-modified diffuser was
used for spherical scattering of the laser light (Naito et al.,
1991). The bladder was filled with physiological saline to an
average volume of 200 mL suffiaent to smooth the mucosal
folds and render the bladder as spherical as possible. The
inital follow-up evaluation was done 3 months after PDT.
The therapeutic clinical efficacy and adverse reactions of
whole bladder wall PDT were followed by periodic exfoliated
urinary cytology, cystoscopy and bladder mucosal biopsy if
necssary, every 3 months after PDT. Complete response
(CR) was defined as no evidence ofcarcinoma ofthe bladder
by cystoscopy, negative urine cytology and negative bladder
mucosal biopse partial response (PR) as positie cytology
and negative bladder mucosal biopsies and no change (NC)
as positive biopsies.
Resell
As shown in Table I, CR rates 3 months after PDT in the
CR, PR and NC groups were 100.0%, 83.5% and 61.1%
resectively, and 73.5% in total. However, visually recog-
nised recurrence occurred in 52.2% of patients within a year
and in 77.8% within 2 years. The cinical course of the CR
patients with primary CIS is shown in Figure 1. All four
patients had recurrece within 11 years; two received tran-
surethral tumour resection and the remaining two underwent
total cystectomy. In patients with secondary CIS who
achieved CR after PDT, disease recurred within I year in
four and within 2 years in two. Five of six patients died of
diseaes other than cancer. Cystectomy was done in two
patiets (Figure 2). In patients with su ial tumours
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TableI Immediate therapeuticclinicalefficacyand recurrence ratein 34patientswhoreceived
whole bladder wall PDT
Follow-up ofCR cases
Recurrence within Recurrence within
Category Number CR (0 ) 1 ear (% 2 years (Go)
Primary CIS 4 4 (100.0) 3/4 (75.0) 4/4 (100.0)
Secondary CIS 12 10 (83.5) 4,8 (50.0) 414 (100.0)
Superficial tumour 18 11 (61.1) 5 11 (45.5) 6, 10 (60.0)
associated with CIS
CIS all 34 25 (73.5) 12/23 (52.2) 14 18 (77.8)
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Table H Long-term outcome in 34patients with refractory carcinoma
in situ of the bladder after PDT
Alive with
Category Number bladder (%}
Primary CIS 4 2 (50.0)
Secondary CIS 12 2 (16.7)
Superficial tumour 18 6 (33.3)
associated with CIS
CIS all 34 10 (29.4)
Follow-up period (months) 64.0
Figure I Outcome in four patients with primary CIS who
achieved complete response after PDT.
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in v v v Figue 3 Outcome in 11 patients with superficial tumours
associated with CIS who achieved complete response after PDT.
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Figue 2 Outcome in ten patients with secondary CIS who
achieved complete response after PDT.
associated with CIS, six of 11 CR patients had recurrence
within 2 years. Two of three dead patients died of other
diseases (Figure 3). Twenty-five of 34 patients achieved CR
and ten of 25 patients with CR after PDT who received TUR
of the bladder cancer for recurrent papillary bladder tumours
were alive with the bladder intact with a mean observation
period of 64.0 months (Table II). Of the patients who
received total cystectomy after PDT, all of those who had
initially achieved a CR were alive; in contrast, four of the
nine patients in the PR and NC groups died of cancer. The
main adverse reactions were haematuria, frequency, skin
photosensitivity and decrease in bladder capacity. As shown
in Figure 4, bladder capacity was temporarily reduced to
approximately 150-200 ml for 1-2 months after PDT. Com-
plications of whole bladder wall PDT in 34 patients are
summarised in Table III.
In this investigation, the authors evaluated the immediate
therapeutic clinical efficacy and long-term outcome of PDT
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Figue 4 Change of urinary bladder capacity after PDT.
in the treatment of 34 patients with superficial bladder
tumours with special reference to CIS. Several physicians
have reported their results with whole bladder wall PDT for
bladder tumours (Hisazumi et al., 1984; Benson, 1986:
D'Hallewin et al., 1992; Uchibayashi et al., 1992) and it is
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Table m Complications ofwhole bladder wall PDT
Imnedately
Sign and symptom after PDT 1 week I month 2 months 3 months
Haematuria 34/34 34/34 0/34 0/34 0/34
Frequency NE 34/34 21/34 9/34 2/34
Buming urination NE 34/34 1/34 0/34 0/34
Skin photosensitivity NE NE 5/34 2/34 1/34
Hydronephrosis NE NE NE NE 2/34
NE, not evaluated.
not an easy task to compare them, since different drugs were
used at different doses and with extrnally measured non-
scattered light dosimetry. The mechanism by which PDT
induced cytotoxic effects has received much attention
(Weishaupt et al., 1976). The differential retention and/or
uptake ofphotosensitising drug by malignant tissue ultimate-
ly is responsible for the preferential destruction of tumour
adjacent to normal surrounding tissue. When exposed to
light of an appropriate wavelength, photosensitisers, such as
HpD, can absorb this energy and become excited, with the
potential for transfer of photons to molecular oxygen or
relaxation of the drug to its ground state. Absorption of this
energy by oxygen results in its transformation to singlet
oxygen and other reactive oxygen radicals. The birth of these
reactive species culminates in cell death, perhaps through
several mechanis. The first cellular changes observed after
PDT begin in mitochondria (Berns et al., 1982) with
cytocidal effects through the results of damage to the tricar-
boxylic acid cycle. The PDT-induced vasoconstriction in the
tumour endothelium may result in an anoxic state that may
also contribute to cell death. In addition, cell membrane
damage by these reactive species has been postulated
(Henderson et al., 1985). In our series of patients with CIS,
25 of 34 patients (73.5%) achieved a complete response at 3
months after PDT. Ten patients were alive with the bladder
intact more than 5 years after PDT. Nevertheless, recurre
within 2 years of follow-up occurred in 14 (77.8%) of the 18
CR patients with CIS. The outcome of PDT in patients with
CIS was compared with that of BCG therapy or cytotoxic
intravesical instillation therapy. PDT appeared to be the
most efficient in immediate therapeutic clinical efficy after
the treatment, compared with the clinical effects of BCG and
cytotoxic treatment (59% and 35% CR respectively) (Prout
et al., 1987; Kavoussi et al., 1988). However, the recurrence
rate within 2 years of PDT was the highest, compared with
the recurre rates after BCG and cytotoxic instillation
therapy of 39% and 31% respectively. This high recurre
rate in PDT should be addressed in future studies. Interest-
ingly, however, most of the tumours recurring after PDT
were superficial low-grade papillary tumours which could be
controlled by TUR. As an outcome, the bladder was retained
in approximately 30% ofpatients with CIS treated with PDT
at a mean follow-up period of 64.0 months. Although the
long-term results, as opposed to the short-term responses,
might be considered rather disappointing, we would like to
emphasise that PDT has clearly had some benefit on the
outcome of a number of patients. The main adverse reac-
tions, photosensitivity and decreases in the bladder capacity,
are probably caused by retention of HpD in the skin or
normal portion of the bladder. The selectivity of HpD is
dependent on the longer retention time of HpD in tumorous
tissue than in normal tissues. It is important to establish the
kinetics of HpD in CIS of the human bladder in order to
achieve the maximum effect of PDT in the tumourous por-
tion and minimum adverse reaction in the normal portion.
To overcome these adverse reactions, a search for a new
photosensitiser, which could accumulate in tumours more
efficiently and be excreted from normal tissues more rapidly,
is a priority. Phthalocyanine appears to be a candidate as a
new photosensitiser based on expenimental data (Komatsu,
1991; Koshida et al., 1993), concerning cytotoxicity, anti-
tumour effect, kinetics and skin photosensitivity.
BENSON RC. (1986). Integral photoradiation therapy of multifocal
bladder tumors. Eur. Urol., 12, 47.
BERNS MW, DAHLMAN A, JOHNSON FM, BURNS R, SPERLING D,
GUILYINAN M, SIEMANS A, WALTER R, WRIGHT W, HAMMER-
WILSON M AND WILE A. (1982). In vitro cellular effects of
bematoporphyrin derivative. Cancer Res., 42, 2325-2329.
CATALONA WJ, HUDSON MA, GILLEN DP, ANDRIOLE GL AND
RATLIFF TL. (1987). Risks and benefits of repeated courses of
intravesical bacilhls Calmette-Guern therapy for superficial
bladdu cancer. J. Urol., 137, 220-224.
D'HALLEWIN MA, BAERT L, MARLNISSEN JPA AND STAR WM.
(1992). Whole bladder wall photodynamic therapy with in situ
light dosimetry for carcinoma in situ ofthe bladder. J. Urol., 148,
1152-1155.
DOUGHERTY TJ, LAURENCE G, KAUFMAN JH, BOYLE DG,
WEISHAUPT KR AND GOLDFARB A. (1979). Photoradiation in
the treatment of recurrent breast cainoma. J. Natil Cancer Inst.,
62, 231-237.
HENDERSON BW, WALDOW SM, MANG TS, POTTER WR, MALONE
PB AND DOUGHERTY T. (1985). Tumor destruction and kinetics
of tumor cell death in two experimental mouse tumors following
photodynamic therapy. Cancer Res., 45, 572-576.
HERR HW, PINSKY CM, WHITMORE WF, SOGANI PC, OEITGEN HF
AND MALAMED MR. (1986). Long-term effect of intravesical
bacillus Calnette-Guerin on flat carcinma in situ of the blad-
der. J. Urol., 135, 265-267.
HISAZUMI H, MIYOSHI N, NAITO K AND MISAKI T. (1984). Whole
bladder wall photoradiation therapy for carcuinoma in situ of the
bladder: a preliminary report. J. Urol., 131, 884-887.
KAVOUSSI LR, TORRENCE RJ, GILLEN DP, HUDSON MA, HAAFF
EO, DRESNER SM, RATLIFF TL AND CATALONA WI. (1988).
Results of 6 weekly intravesical bacillus Calmette-Guerin instil-
lations on the treatment of superficial bladder tumors. J. Urol.,
139, 935.
KOMASITU K- (1991). Photodynamic cell killing effects and acute skin
photosensitivity of ahmfinium-chloro-tetrasulphonated phthalo-
cyanine and bematoporphyrin derivative. Jpn J. Cancer Res., 82,
599-606.
KOSHIDA K, HISAZUMI H, KOMATSU K, HIRATA A AND
UCHIBAYASHI T. (1993). Possible advantages of aluminium-
chloro-tetrasulfonated phthalocyanine over hematoporphyrin
derivatives as a photosensitizer in photodynamic therapy. Urol.
Res., 21, 283-288.
LAMM DL, STOGDILL VD, STOGDILL BJ AND CRISPEN RG. (1986).
Complications of baillus Calmette-Guerin immunotherapy in
1,278 patients with bladder canr. J. Urol., 135, 272-274.
NAITO K, HISAZUMI H, UCHIBAYASHI T, AMANO T, HIRATA A,
KOMATSU K, ISHIDA T AND MIYOSHI N. (1991). Integral laser
photodynamic treatment of refractory multifocal badder tumors.
J. Urol., 146, 1541-1545.
PROUT GR, GRIFFIN PP, DALY RJI AND HENEY NM. (1983). Car-
cinoma in situ of the urinary bladder with and without associated
vesical neoplasms. Cancer, 52, 524-532.
PROUT GR, GRIFFIN PP AND DALY JJ. (1987). The outcome of
conservative treatment of carcinoma in situ of the bladder. J.
Urol., 138, 766-780.PDT br bi_ csa
T Uchibayash et a
UCHIBAYASHI T, HISAZUMI H, KOSHIDA K AND MIYOSHI N.
(1992). Integral photodynamic therapy of refractory superficial
bladder tumors. In Photodnic Therapy and Biomedical lasers,
Spinelli P, Dal Fante M and Marxhesini R (eds) pp. 997-1001.
Elsevier Amsterdam.
UTZ DC, HANASH KA AND FARROW GM. (1970). The plight of the
patient with carcinoma in situ of the bladder. J. Urol., 103,
160-164.
WEISHAUPT KR, GOMER CJ AND DOUGHERTY TJ. (1976).
Identification of singlet oxygen as the cytotoxic agent in
photoinactivation of a murine tumor. Cancer Res., 36,
2326-2329.